Oct 22 (Reuters) - Amgen Inc, which this monthclosed a nearly $10 billion acquisition of cancer drug makerOnyx Pharmaceuticals, reported a higher third-quarter profit,helped by an 18 percent increase in sales of its white bloodcell boosters.
The world's largest biotechnology company said on Tuesdaynet profit rose to $1.37 billion, or $1.79 per share, from $1.1billion, or $1.41 per share, a year ago.
Amgen also raised its full year revenue forecast and pushedup the low end of its earnings forecast range by 5 cents. Thecompany now expects 2013 adjusted earnings of $7.35 to $7.45 pershare and sees revenue of $18.3 billion to $18.5 billion, upfrom its previous view of $17.8 billion to $18.2 billion.
- Health Care Industry
- Company Earnings
- Amgen Inc
- Onyx Pharmaceuticals